(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 July 2024 (11.07.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/147897 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)
C07K 19/00 (2006.01)

(21) International Application Number:
PCT/US2023/083985

(22) International Filing Date:
14 December 2023 (14.12.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/478,640 05 January 2023 (05.01.2023) US
63/496,159 14 April 2023 (14.04.2023) US

(71) Applicant: **HARPOON THERAPEUTICS, INC.** [US/US]; 611 Gateway Blvd., Suite 400, South San Francisco, California 94080 (US).

(72) Inventors: **WESCHE, Holger**; 611 Gateway Blvd., Suite 400, South San Francisco, California 94080 (US). **LIN, Shuoyen Jack**; 611 Gateway Blvd., Suite 400, South San Francisco, California 94080 (US). **WRIGHT, Kevin J.**; 611 Gateway Blvd., Suite 400, South San Francisco, California 94080 (US). **AUSTIN, Richard J.**; 611 Gateway Blvd., Suite 400, South San Francisco, California 94080 (US).

(74) Agent: **ATKINS, Benjamin D.** et al.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: TROP2 TARGETING TRISPECIFIC PROTEIN FOR TREATMENT OF CANCER



FIG. 26

(57) Abstract: Provided herein are TROP2 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such TROP2 binding proteins. Also disclosed are methods of using the disclosed TROP2 binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

WO 2024/147897 A3

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
19 September 2024 (19.09.2024)